Central Nervous System Lymphomas (Ongoing)

Evidence on the diagnosis and treatment of patients with CNS lymphomas as well asour knowledge in the biological and molecular profiles of this disease grew very fastin the latest years, and contribution of experts is important to put in context reportedstudies, draw recommendations and delineate future research. We feel it is important to dedicate a special issue on Central Nervous System Lymphomas and aim to provide an updated overview of the most recent acquisitions and future perspectives.

Read More>>

AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers

AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020. Around 60 AME journals’ peer review systems are now integrated seamlessly into the Publons platform (https://publons.com/about/home). The partnership was done to recognize our expert peer reviewers spontaneously for their review contribution.

Read More>>

AOL Annual Report (2019)

Greetings from Editor-in-Chief and Editorial Office of Annals of Lymphoma!

We are pleased to share the 2019 Annual Report of Annals of Lymphoma here.

We would especially like to express our sincere gratitude to the editorial board members, guest editors, reviewers, authors and readers for all your support and contributions to Annals of Lymphoma from the inception of the journal. We warmly welcome more experts’ joining and hope to work more with you to make the journal a robust and vigorous platform! Wish you a happy, healthy and prosperous 2020!

Read More>>

Diffuse Large B-Cell Lymphoma

In this issue, we present the current state of diagnosis and treatment of DLBCL. We have carefully selected experts in the each topic to provide an instructive review of the literature and their personal interpretation of the data. We hope this focused issue provides readers with analyzed information that will help them face or overcome the mentioned challenges with useful and evidenced based information..

Read More>>

Application of the CARE Guideline as reporting standard in the Annals of Lymphoma

The Annals of Lymphoma welcomes case reports which are supposed to report new observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the fields of medicine.

For completeness and transparency for published case reports, the Annals of Lymphoma will apply the CARE guidelines (1) as reporting standards for case reports starting from October 14, 2019. 

Read More>>

Annals of Lymphoma forms partnership with lymphoma research foundation

In 2011, the U.S. Congress declared the month of September to be Blood Cancer Awareness Month. The designation was intended to bring much-deserved attention to the needs of patients and for increased investment in biomedical research. Since that time, more than a half million Americans have received a lymphoma or chronic lymphocytic leukemia (CLL) diagnosis. And despite numerous programs intended to accelerate the pace of cancer research, the need for new resources to support blood cancer research has never been greater.

Read More>>

Welcome to Annals of Lymphoma

During my formative years, a textbook of hematology would contain a single, rather brief, chapter on lymphomas. Within the pages would be clinical and pathologic descriptions in broad terms relating to a limited number of recognized histologic subtypes. As our knowledge increased, the chapters were separated into Hodgkin and non-Hodgkin, and then the latter into B- and T-cell. Treatment strategies from that period relied heavily on radiation therapy, but eventually active systemic treatment was available, although founded on those derivatives of mustard gas, the alkylating agents, as well as corticosteroids, and a series of other non-specific cytotoxic drugs. Means to assess response were rudimentary and variable, including radiographs, lymphangiograms and ultrasounds. It was totally unclear why some patients with a similar histologic morphology would be cured, whereas others were resistant to similar treatments. In this context, the glacial speed of journal publications was sufficient.

Read More>>